Artiva Biotherapeutics
- Biotech or pharma, therapeutic R&D
Artiva (NASDAQ: ARTV) is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with autoimmune diseases and cancers. Artiva’s robust manufacturing platform produces thousands of 1 billion-cell vials of NK cells from a single umbilical cord blood unit.
Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies. AlloNK is delivered in the outpatient setting with no required hospitalization. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases: two company-sponsored trials across multiple autoimmune diseases including RA, SLE, LN and Sjögren’s disease, as well as an investigator-initiated basket trial. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}